Canadian Diabetes
Published quarterly, Canadian Diabetes provides practical, current information to family physicians on diagnosis and treatment issues associated with diabetes.
Levelling the Bumps: New Therapies Aimed at Postprandial Hyperglycemia
The papers in this issue of Canadian Diabetes highlight the importance of postprandial glucose control, and the medications expected to arrive on the Canadian marketplace over the next 1 to 2 years that act on the incretin system, in part helping to smooth out postprandial hyperglycemia.
Sarah Capes MD MSc FRCPC, Sara Meltzer MD FRCPC
Pour aplanir les pics glycémiques : nouveaux traitements agissant sur l’hyperglycémie postprandiale
Les articles de ce numéro de Le diabète au Canada font ressortir l’importance du contrôle de la glycémie postprandiale et présentent les médicaments ayant un effet incrétine, qui contribue à aplanir les pics hyperglycémiques postprandiaux, qui feront possiblement leur entrée sur le marché canadien d’ici un an ou deux.
Sarah Capes MD MSc FRCPC, Sara Meltzer MD FRCPC
The Incretin-based Drugs: Promising New Therapies for the Treatment of Type 2 Diabetes
Currently, several classes of medications that reduce hyperglycemia through diverse mechanisms are used, either as monotherapy or in combination, for the treatment of type 2 diabetes (1) (Table 1).
Laurie L. Baggio PhD
Treating the Spikes: Is Targeting Postprandial Hyperglycemia Important in Type 2 Diabetes?
Large interventional studies have clearly shown that achieving and maintaining nearnormal glycemic levels reduces the risk for microvascular complications in type 2 diabetes (1).
Robyn L. Houlden MD FRCPC
Canadian Diabetes Winter 2007 - Full Issue
Production of materials has been made possible through a financial contribution from the Public Health Agency of Canada.
© 2012 Copyright Canadian Diabetes Association